Skip to main content

Accelerating Preclinical Development of Cell Engagers with Cell Avidity

Part of: Cell engagers

Accelerating Preclinical Development of Cell Engagers with Cell Avidity

Accelerating Preclinical Development of Cell Engagers with Cell Avidity

Cell Engagers (CE) or bispecific antibodies are molecules that can steer immune cells, such as T cells, NK cells, and macrophages, towards cancer cells. 

Did you know that more than 90% of immuno-oncology drugs (including CEs) entering phase I clinical trials fail to meet expectations due to poor efficacy and/or severe side effects? 

Conventional in vitro methods used for characterizing Cell Engagers during preclinical development often produce inconclusive outcomes. This drawback leads to the selection of suboptimal candidates for in vivo testing and, in some cases, even for Investigational New Drug (IND) filings. This limitation significantly hampers progress, leaving drug developers vulnerable to failures at crucial stages of their journey. 

Learn more about how Cell Avidity can accelerate your preclinical workflows and path to successful IND filings

Improve decision making with high throughput avidity readouts

The incorporation of measuring avidity at high throughput at the outset of preclinical development brings forth an invaluable additional data point that was previously absent. 

Findings derived from measuring the avidity of T-cells, in the presence of CEs, reveal unique information on the functional binding between effector and tumor cells. This provides researchers with more confidence in lead candidate selection by providing better differentiation between lead CEs compared to traditional in vitro assays

Our solutions

Cell avidity as a service

Cell Avidity analysis can be performed at high throughput using our services platform, enabling the screening of hundreds of Cell Engagers to rapidly find the most potent Cell Engager for in vivo testing. 

Dr. Rogier Reijmers
Principal Scientist at LUMICKS

Download the brochure to learn more

Join our mailing list

I would like to receive exclusive news about the latest product developments, dynamic single-molecule and immuno-oncology events and breakthrough science. I can revoke my consent at any time.

By submitting the form you agree to LUMICKS' privacy policy.

Close Menu

For pricing, reach out to your application scientist or account manager

Open Email

Fill in our contact form, we will reach out to you!

Please include ‘Lakeview data analysis price inquiry’ in the Message box

Contact Us

Join our newsletter

Get exclusive news on the latest publications, product developments, events and breakthrough science.

By submitting the form you agree to LUMICKS' privacy policy. You can revoke your consent at any time.

Download our webinar recording:


Download our Cell Therapy (CAR-T, TCR, NK) applications deck